Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Oakridge Institute for Science and Education, Atlanta, Georgia, USA.
Transfusion. 2023 Oct;63 Suppl 4(Suppl 4):S1-S7. doi: 10.1111/trf.17359. Epub 2023 Apr 13.
Reports have suggested the COVID-19 pandemic resulted in blood donation shortages and adverse impacts on the blood supply. Using data from the National Blood Collection and Utilization Survey (NBCUS), we quantified the pandemic's impact on red blood cell (RBC) and apheresis platelet collections and transfusions in the United States during year 2020.
The 2021 NBCUS survey instrument was modified to include certain blood collection and utilization variables for 2020. The survey was distributed to all US blood collection centers, all US hospitals performing ≥1000 surgeries annually, and a 40% random sample of hospitals performing 100-999 surgeries annually. Weighting and imputation were used to generate national estimates for whole blood and apheresis platelet donation; RBC and platelet transfusion; and convalescent plasma distribution.
Whole blood collections were stable from 2019 (9,790,000 units; 95% CI: 9,320,000-10,261,000) to 2020 (9,738,000 units; 95% CI: 9,365,000-10,110,000). RBC transfusions decreased by 6.0%, from 10,852,000 units (95% CI: 10,444,000-11,259,000) in 2019 to 10,202,000 units (95% CI: 9,811,000-10,593,000) in 2020. Declines were steepest during March-April 2020, with transfusions subsequently rebounding. Apheresis platelet collections increased from 2,359,000 units (95% CI: 2,240,000-2,477,000) in 2019 to 2,408,000 units (95% CI: 2,288,000-2,528,000) in 2020. Apheresis platelet transfusions increased from 1,996,000 units (95% CI: 1,846,000-2,147,000) in 2019 to 2,057,000 units (95% CI: 1,902,000-2,211,000) in 2020.
The COVID-19 pandemic resulted in reduced blood donations and transfusions in some months during 2020 but only a minimal annualized decline compared with 2019.
有报道称，COVID-19 大流行导致了血液捐献短缺，并对血液供应造成了不利影响。我们利用国家血液采集和利用调查（NBCUS）的数据，量化了 2020 年美国 COVID-19 大流行对红细胞（RBC）和单采血小板采集和输注的影响。
对 2021 年 NBCUS 调查工具进行了修改，以纳入 2020 年某些血液采集和利用变量。该调查向所有美国血液采集中心、每年进行≥1000 例手术的所有美国医院以及每年进行 100-999 例手术的医院的 40%随机样本分发。使用加权和插补来生成全血和单采血小板捐献、RBC 和血小板输注以及恢复期血浆分布的全国估计数。
全血采集量在 2019 年（979 万单位；95%置信区间：932 万至 1026.1 万）和 2020 年（973.8 万单位；95%置信区间：936.5 万至 1011.0 万）之间保持稳定。RBC 输注量下降了 6.0%，从 2019 年的 1085.2 万单位（95%置信区间：1044.4 万至 1125.9 万）降至 2020 年的 1020.2 万单位（95%置信区间：981.1 万至 1059.3 万）。2020 年 3 月至 4 月期间降幅最大，随后输注量反弹。单采血小板采集量从 2019 年的 235.9 万单位（95%置信区间：224 万至 247.7 万）增加到 2020 年的 240.8 万单位（95%置信区间：228.8 万至 252.8 万）。单采血小板输注量从 2019 年的 199.6 万单位（95%置信区间：184.6 万至 214.7 万）增加到 2020 年的 205.7 万单位（95%置信区间：190.2 万至 221.1 万）。
COVID-19 大流行导致 2020 年某些月份的血液捐献和输注减少，但与 2019 年相比，年化降幅很小。
